Therapeutics
Pharmacologic cyclin-dependent kinase inhibitors (PCI) are promising new drugs for a number of proliferative and immunologic renal diseases. The specificity, efficacy, toxicity, and alternative target activity of PCI, particularly on glycogen synthase kinase-3 and the aryl hydrocarbon receptor, are being studied in models of collapsing glomerulopathy.